Friday, 10 Apr 2020

You are here

Hyperuricemia Predisposes to Coronary Artery Disease in Men

There are numerous associations between hyperuricemia and cardiovascular disease (CVD). An analysis of the Swedish SCAPIS Pilot study shows that higher levels of serum urate (SU) are associated with an increase in coronary artery calcification (CAC) score in men but not in women. SU is not associated with common carotid intima-media thickness (CIMT), and carotid plaque scores in either men or women.

Swedish CArdioPulmonary bioImage Study (SCAPIS) Pilot cohort (N = 1040; 48.8% males) is a population based cohort study to examine CVD risk and prediction in 30,000 participants in the age range of 50-64 years.  

Analysis of predictive factors showed showed no differences between males and females with regard to age, BMI, education level, smoking, physical activity, hs-CRP, hypertension, and dyslipidemia.

CAC (score > 0) and diabetes were both twice as common in men than in women (58% vs 26% and 8% vs 4%, respectively).

Higher SU quartiles (in both sexes) were associated with BMI, hs-CRP, and the prevalence of hypertension, and in women, they were also associated with the prevalence of dyslipidemia.

The three upper quartiles of SU (>308μmol/L) were linked to higher CAC scores in men, when adjusting for CVRFs, but not in women. CIMT and carotid plaques showed no correlation to SU in either sex.

It appears that the vascular effects of SU differ in men and women.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Interleukin-37 Targeting in Gout

The Annals of Rheumatic Disease reports that interleukin- 27 (IL-37) may play an important role in the pathogenesis of gout, paving the way for future therapy with recombinant IL-37 in gouty arthritis.

Activation of the inflammasome by monosodium urate crystals is thought to be paramount to the innate immune response that drives IL-1-mediated joint inflammation in gout.

Hypersensitivity Reactions and Gout Tx: Watch the Dose

Both allopurinol and febuxostat (Uloric) were associated with an increased risk of hypersensitivity reactions among new users of these urate-lowering therapies, a large U.S. study found.

Diabetics using SGLT2 Inhibitors have a lower Gout Risk

Researchers from the Brigham and Women's Hospital have reported that adults with type 2 diabetes who were treated with SGLT2 inhibitors had a lower risk of gout compared to GLP1 agonist, suggesting that sodium–glucose cotransporter-2 inhibitors may reduce the risk for gout with type 2 diabetes mellitus (T2DM).

A Role for SGLT2 Inhibition in Gout?

The antidiabetic medication canagliflozin (Invokana) lowered serum urate and reduced the risk of gout flare in a post-hoc analysis of data from two large clinical trials.

Predicting Inpatient Gout Flares

Analysis of New Zealand hospitalized patients revals nine predictors of inpatient flare for people with comorbid gout.

This retrospective cohort study of hospitalised patients with comorbid gout included 625 hospitalised patients, 87 experienced inpatient gout flare.

There were 9 predictors of an inpatient gout flare: